U.S. regulators have approved the first drug for bladder cancer that harnesses the body's immune system. It is the first advance in decades against the most common type of bladder cancer, one which almost always kills patients within months.
Tecentriq (TEE'-sehn-trik) won approval for treating patients with advanced urothelial cancer after chemotherapy stops helping them.
FDA OKs immunotherapy drugs for bladder, blood cancers
Aucun commentaire:
Enregistrer un commentaire